Adjuvant incorporation in immunonanotherapeutics
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/40
A61K-039/395
A61K-049/04
출원번호
US-0123888
(2009-10-09)
등록번호
US-8637028
(2014-01-28)
국제출원번호
PCT/US2009/060242
(2009-10-09)
§371/§102 date
20110720
(20110720)
국제공개번호
WO2010/042870
(2010-04-15)
발명자
/ 주소
Alexis, Frank
Iannacone, Matteo
Shi, Jinjun
Basto, Pamela
Moseman, Elliott Ashley
von Andrian, Ulrich
Langer, Robert S.
Farokhzad, Omid C.
Tonti, Elena
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
60인용 특허 :
167
초록▼
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface a
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
대표청구항▼
1. A composition comprising: (1) polymeric synthetic nanocarriers comprising an immunofeature surface formed of an array of binding moieties, the array binding to dendritic or subcapsular sinus macrophages with high avidity and low affinity as compared to antibody binding; and(2) a pharmaceutically
1. A composition comprising: (1) polymeric synthetic nanocarriers comprising an immunofeature surface formed of an array of binding moieties, the array binding to dendritic or subcapsular sinus macrophages with high avidity and low affinity as compared to antibody binding; and(2) a pharmaceutically acceptable excipient. 2. The composition of claim 1, comprising an immunostimulatory agent. 3. The composition of claim 1, comprising MHC Class I, MHC Class II or CD-1 presentable polypeptide associated with the immunofeature surface; associated with a second surface of the nanocarrier; or encapsulated within the nanocarrier. 4. The composition of claim 1, wherein the immunofeature surface is formed of a plurality of moieties that are present in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell (APC) binding assay. 5. The composition of claim 4, comprising an immunostimulatory agent, wherein the half maximal binding density for the immunostimulatory agent is at least twice the half maximal binding density for the MAb and the immunostimulatory agent is present in a density equal to or greater than the density required to obtain at least 20% of the maximal immobilization observed for a MAb in a APC binding assay. 6. The composition of claim 5, wherein the half maximal binding density for the immunostimulatory agent is at least four times the half maximal binding density for the MAb. 7. The composition of claim 4, wherein the APC binding assay comprises: (a) preparing a series of substrates having coatings of an functional moiety at a series of surface coating densities, wherein the functional moiety is capable of binding to dendritic cell (DC) or subcapsular sinus macrophage surface receptors;(b) exposing the series of substrates to single-cell suspensions of DCs or subcapsular sinus macrophage for a predetermined period of time;(c) removing non-adhered APCs from the series of substrates, and fixing the adhered APCs to the series of substrates;(d) quantifying the number of adhered APCs per unit surface area for each substrate in the series of substrates;(e) plotting the result from (d) against the coating density of the functional moiety;(f) obtaining a value for the maximal immobilization by determining the maximum number of adhered APCs per unit surface area for the series of substrates; and(g) obtaining a value for half maximal binding density by determining the surface coating density that provides 50% of the maximum. 8. The composition of claim 4, wherein the MAb is anti-CD1c (BDCA-1) Clone AD5-8E7 or rat anti-mouse CD169 clone 3D6.112. 9. The composition of claim 2, wherein immunostimulatory agent is a Toll-Like Receptor (TLR) agonist. 10. The composition of claim 9, wherein the TLR agonist is a TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, or TLR-10 agonist. 11. The composition of claim 2, wherein the immunostimulatory agent is selected from an interleukin, an interferon, a cytokine, and an adjuvant. 12. The composition of claim 1, wherein the composition is capable of providing enhanced T-cell proliferation in a human subject. 13. The composition of claim 1, wherein the composition elicits dendritic cell maturation when administered to a human subject. 14. The composition of claim 1, wherein the nanocarriers comprises two or more different MHC Class I, MHC Class II or CD 1 presentable polypeptides. 15. The composition of claim 1, wherein the composition comprises two or more immunostimulatory agents. 16. The composition of claim 15, wherein the composition comprises two or more Toll-Like Receptor (TLR) agonists. 17. The composition of claim 15, wherein the composition comprises one Toll-Like Receptor (TLR) agonist and one non-TLR agonist. 18. The composition of claim 17, wherein the non-TLR agonist is a moiety that induces signaling through the inflammasome, CD40, or a cytokine receptor. 19. The composition of claim 3, wherein the MHC Class I presentable peptide is selected from the group consisting of SIINFEKL (SEQ ID NO:1), GP33, Core 18-27, and MAGE. 20. The composition of claim 3, wherein the MHC Class II presentable peptide is selected from the group consisting of GP61, MAGE-A4 280-299, tetanus toxoid, diphtheria toxoid, and PADRE peptide. 21. The composition of claim 3, wherein the CD1 presentable peptide is selected from the group consisting of mycolic acid, sulpholipids, lipophosphoglycan, diacylglycerols, glycoshpingolipids, alpha-galactosylceramide, isoglobotrihexosylceramide, and ganglioside GD3. 22. The composition of claim 1, further comprising an immunomodulatory agent selected from the group consisting of proteins, peptides, carbohydrates, glycoproteins, glycopeptides, proteoglycans, inactivated organisms and viruses, dead organisms and virus, genetically altered organisms or viruses, antigens of fungal organisms, protozoan organisms, parasitic organisms, and cell extracts. 23. A method comprising: administering to a subject an initial dose of a composition comprising:polymeric synthetic nanocarriers comprising an immunofeature surface formed of an array of binding moieties, the array binding to dendritic or subcapsular sinus macrophages with high avidity and low affinity as compared to antibody binding; anda pharmaceutically acceptable excipient; andadministering to the subject a first subsequent dose of the composition at a time period after the administration of the initial dose. 24. The method of claim 23, wherein the time period is an interval ranging from 1 day to 1 year. 25. The method of claim 23, wherein the first dose of the composition elicits T-cell proliferation in the subject. 26. The method of claim 23, wherein one week after administration of the initial dose the blood concentration of antigen-specific T cells in the subject is at least 10-fold higher than the concentration of T cells recognizing an irrelevant antigen to which the subject has no immunological memory. 27. The method of claim 26, wherein the irrelevant anitigen is bovine serum albumin. 28. The method of claim 23, wherein one week after administration of the first subsequent dose the blood concentration of antigen-specific T cells in the subject is at least 10-fold higher than the concentration of T cells recognizing an irrelevant antigen to which the subject has no immunological memory. 29. The method of claim 28, wherein the irrelevant antigen is bovine serum albumin. 30. The composition of claim 1, wherein the moieties are present in an amount effective to provide avidity-based binding to binding to mammalian antigen presenting cells. 31. The composition of claim 1, wherein the diameter of the nanocarriers is greater than 100 nm. 32. The composition of claim 1, wherein the pharmaceutically acceptable excipient is selected from the group consisting of solvents, dispersion media, diluents, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants. 33. The composition of claim 1, wherein the composition targets a dendritic cell. 34. The composition of claim 1, wherein the composition does not substantially activate complement.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (167)
Gerster John F. (Woodbury MN) Crooks Stephen L. (Mahtomedi MN) Lindstrom Kyle J. (Houlton WI), 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines.
Schmitz,Juergen; Dzionek,Andrzej; Buck,David William, Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Mikos Antonios G. (Houston TX) Sarakinos Georgios (Boston MA) Vacanti Joseph P. (Winchester MA) Langer Robert S. (Newton MA) Cima Linda G. (Lexington MA), Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
D\Amore Patricia (Brookline MA) Leong Kam W. (Cambridge MA) Langer Robert S. (Somerville MA), Bioerodible articles useful as implants and prostheses having predictable degradation rates.
Skwierczynski Raymond D. ; Phares Kenneth R. ; Miller Richard L. ; Li Zheng Jane ; Jozwiakowski Michael J. ; Busch Terri F., Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
Dalton,James T.; Miller,Duane D.; Steiner,Mitchell S.; Veverka,Karen A., Halogenated selective androgen receptor modulators and methods of use thereof.
Swain Philip A. ; Schad Victoria C. ; Greenstein Julia L. ; Exley Mark A. ; Fox Barbara S. ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Kedl,Ross M.; Griesgraber,George W.; Zarraga,Isidro Angelo E.; Wightman,Paul D., Immunostimulatory compositions and methods of stimulating an immune response.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Bengs, Holger; Grande, Jürgen; Schuth, Silke; Böhm, Gitte; Schneller, Arnold; Brunner, Anette, Method for preparing smooth-surface spherical microparticles completely or partially made of at least one water-insoluble linear polysaccharide and microparticles produced according to this method.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Jacobson Stephen C. ; Ramsey J. Michael, Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same.
Horoszewicz Julius S. (Williamsville NY), Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bischofberger Norbert W. ; Jones Robert J. ; Arimilli Murty N. ; Lin Kuei-Ying ; Louie Michael S. ; McGee Lawrence R. ; Prisbe Ernest J. ; Lee William A. ; Cundy Kenneth C., Nucleotide analogs.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Cech Thomas R. (Boulder CO) Zaug Arthur J. (Louisville CO) Been Michael D. (Boulder CO), RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Larry Gold ; Michael Willis ; Tad Koch ; Steven Ringquist ; Kirk Jensen ; Brent Atkinson, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, In vivo production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of biologics and proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of biologics and proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of oncology-related proteins and peptides.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; Ellsworth, Jeff Lynn; Ejebe, Kenechi; Guild, Justin; John, Matthias; Hatala, Paul; Roy, Atanu; Schrum, Jason P.; Whoriskey, Susan; Wood, Kristy M., Modified polynucleotides for the production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of secreted proteins.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.